| Literature DB >> 20402593 |
Jeffrey A Canter1, Gregory K Robbins, Doug Selph, David B Clifford, Asha R Kallianpur, Robert Shafer, Shawn Levy, Deborah G Murdock, Marylyn D Ritchie, David W Haas, Todd Hulgan.
Abstract
Susceptibility to peripheral neuropathy during antiretroviral therapy with nucleoside reverse-transcriptase inhibitors was previously associated with a European mitochondrial DNA (mtDNA) haplogroup among non-Hispanic white persons. To determine whether nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy was related to mtDNA variation in non-Hispanic black persons, we sequenced mtDNA of participants from AIDS Clinical Trials Group study 384. Of 156 non-Hispanic black persons with genomic data, 51 (33%) developed peripheral neuropathy. In a multivariate model, African mtDNA subhaplogroup L1c was an independent predictor of peripheral neuropathy (odds ratio, 3.7 [95% confidence interval, 1.1-12.0]). An African mtDNA subhaplogroup is for the first time implicated in susceptibility to nucleoside reverse-transcriptase inhibitor-associated toxicity.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20402593 PMCID: PMC2862090 DOI: 10.1086/652419
Source DB: PubMed Journal: J Infect Dis ISSN: 0022-1899 Impact factor: 5.226